Creative Medical Technology Holdings Inc. - Utang kumulatif perusahaan CELZ

Creative Medical Technology (CELZ) relies on outsourcing clinical trials to external centers while maintaining full control over its proprietary developments. The business is based on creating regenerative drugs for urology and immunology, leveraging an extensive patent portfolio. On the GURU.Markets platform, the visualized share price action is 0.00, confirming the success of unique AmnioStem products for treating male infertility in niches ignored by industry behemoths.

Total liabilities measure the aggregate of short-term and long-term borrowings, allowing for an assessment of financial stability and the cost of capital servicing through the organization's debt profile. For Creative Medical Technology (CELZ), which relies on costly clinical trials and venture financing in the absence of profits, this indicator is critical for monitoring solvency risks and evaluating management's ability to sustain operational activities.